<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1614">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140148</url>
  </required_header>
  <id_info>
    <org_study_id>849451</org_study_id>
    <nct_id>NCT05140148</nct_id>
  </id_info>
  <brief_title>Promoting Recovery After STroke With Amantadine</brief_title>
  <acronym>PRESTA</acronym>
  <official_title>Promoting Recovery After STroke With Amantadine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aim to examine whether amantadine can help patients recover from stroke.&#xD;
      This will be a blinded randomized clinical trial (RCT). Patients will be randomized&#xD;
      post-ischemic or hemorrhagic stroke either to the placebo arm or amantadine arm. Patients&#xD;
      will be on study drug or placebo for 1 month but will be enrolled for 3 months total. At&#xD;
      various time points they will be examined and fill out questionnaires to determine their&#xD;
      level of stroke recovery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Day 90</time_frame>
    <description>Tolerability of the study drug will be assessed based on the proportion of patients who adherent with at least 80% of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global rating on the Stroke Impact Scale (SIS)</measure>
    <time_frame>90 days</time_frame>
    <description>Patient reported measure of stroke recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score on the National Institute of Health Stroke Scale (NIHSS)</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment for stroke deficits in patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Digit Symbol Substitution Test (DSST) score</measure>
    <time_frame>90 Days</time_frame>
    <description>Cognitive test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment test (MOCA) score</measure>
    <time_frame>90 Days</time_frame>
    <description>Cognitive test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Health Questionnaire (PHQ-9) score</measure>
    <time_frame>90 days</time_frame>
    <description>Patient reported survey of depression symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Upper limb strength</measure>
    <time_frame>90 Days</time_frame>
    <description>The upper limb strength for each subject with be measured using a hand dynamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Score (mRS)</measure>
    <time_frame>90 days</time_frame>
    <description>Assessment of post-stroke recovery</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Stroke Hemorrhagic</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill, twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amantadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg amantadine twice daily, or if 65 years or older once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amantadine</intervention_name>
    <description>Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease</description>
    <arm_group_label>Amantadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 85 years old, male and female&#xD;
&#xD;
          2. Modified Rankin Score (mRS)&lt;=2 prior to stroke&#xD;
&#xD;
          3. Ischemic or hemorrhagic stroke as diagnosed by vascular neurologist or as proven on&#xD;
             magnetic resonance imaging (MRI) or non-contrast head computed tomography NCHCT)&#xD;
&#xD;
          4. 24 hours to 3 weeks after stroke onset or time last known well prior to detection of&#xD;
             symptoms&#xD;
&#xD;
          5. National Institute of Health Stroke Scale (NIHSS)&gt;=3 and NIHSS&lt;=15&#xD;
&#xD;
          6. Creatinine Clearance of greater than or equal to 60 mL/min using the Cockroft- Gault&#xD;
             equation.&#xD;
&#xD;
          7. Have passed a swallow evaluation prior to drug administration&#xD;
&#xD;
          8. The patient is an acute rehabilitation candidate or candidate for the Homeward Stroke&#xD;
             Program&#xD;
&#xD;
          9. Able to participate in administered tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any degree of receptive aphasia&#xD;
&#xD;
          2. Moderate or severe expressive aphasia&#xD;
&#xD;
          3. Currently pregnant or plans to get pregnant&#xD;
&#xD;
          4. Currently breastfeeding&#xD;
&#xD;
          5. Any patient admitted with primary SubarachnoidH emorrhage (SAH )on either non-contrast&#xD;
             head CT or MRI brain&#xD;
&#xD;
          6. Diagnosis of dementia or mild cognitive impairment prior to index stroke&#xD;
&#xD;
          7. Prior limb amputation&#xD;
&#xD;
          8. Currently prescribed or taking a primary anticholinergic medication&#xD;
&#xD;
          9. Currently enrolled in any other investigational pharmacologic or procedural clinical&#xD;
             trial&#xD;
&#xD;
         10. Malignancy with active treatment&#xD;
&#xD;
         11. History of prior stroke with residual impairment&#xD;
&#xD;
         12. Current or prior neuroleptic use&#xD;
&#xD;
         13. History of suicidality or psychosis (The Columbia Suicide Severity Ratings Scale&#xD;
             (C-SSRS) will be administered at the screening visit to assess depression and suicidal&#xD;
             thoughts for subject eligibility. Any subjects who indicate severe depression or&#xD;
             suicidal thoughts and/or attempts within the last year will not be eligible)&#xD;
&#xD;
         14. Prior history of seizures&#xD;
&#xD;
         15. Prior treatment with amantadine&#xD;
&#xD;
         16. Parkinson's disease&#xD;
&#xD;
         17. Amantadine allergy&#xD;
&#xD;
         18. Elevated liver function tests (aspartate aminotransferase and alanine aminotransferase&#xD;
             above the upper limit of normal) -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aaron Rothstein, M.D</last_name>
    <phone>267-624-4442</phone>
    <email>aaron.rothstein@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nichole Gallatti, M.S.Ed.</last_name>
    <email>nichole.gallatti@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Scott Kasner, MD</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Hemorrhagic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amantadine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

